CCIA
KYMR icon

Campbell & Co Investment Adviser’s Kymera Therapeutics KYMR Stock Holding History

Campbell & Co Investment Adviser’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,534
Closed -$897K – 1250
2025
Q4 		$897K Buy
11,534
+6,963
+152% +$470K 0.04% 606
2025
Q3 		$259K Buy
+4,571
New +$206K 0.02% 951
2025
Q1 		– Sell
-18,519
Closed -$745K – 1184
2024
Q4 		$745K Sell
18,519
-11,689
-39% -$528K 0.06% 512
2024
Q3 		$1.43M Sell
30,208
-767
-2% -$33.9K 0.11% 301
2024
Q2 		$925K Sell
30,975
-3,720
-11% -$129K 0.08% 396
2024
Q1 		$1.39M Buy
34,695
+3,598
+12% +$129K 0.12% 258
2023
Q4 		$792K Buy
+31,097
New +$556K 0.07% 488

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Campbell & Co Investment Adviser's KYMR Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 11,534 shares — an estimated $897K sold.

Campbell & Co Investment Adviser first reported a position in KYMR in Q4 2023 and held it in 7 quarters. The position peaked at $1.43M in Q3 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 11,534 Kymera Therapeutics shares in Q1 2026, an estimated $897K.
  • Campbell & Co Investment Adviser first reported a position in Kymera Therapeutics in Q4 2023 and held it in 7 quarters.
  • Campbell & Co Investment Adviser's Kymera Therapeutics position peaked at $1.43M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.